需要帮助?我们经验深厚的专家团队,随时为您提供全力支持。
产品编号
AKA-388
CAS号码
2803478-47-7
分子式
C17H18N6.1/2C4H4O4
分子量
728.80
鲁索利替尼半富马酸盐
Ruxolitinib Hemifumarate
2803478-47-7
C17H18N6.1/2C4H4O4
728.80
98.0%~102.0%
Certificate of Analysis (COA), API specification sheet, Safety Data Sheet (SDS/MSDS), evidence of GMP compliance, Stability data / Stability summary, etc.
鲁索替尼半富马酸盐是一种选择性 Janus 激酶(JAK)1 和 JAK2 抑制剂,属于吡咯并嘧啶类化合物。 包装: 100g/袋,500g/袋,1kg/袋,5kg/袋 供货情况: 现货供应 API Current Development Status: A3---Process Development / Scale-Up Reference: Aktin major API development processes: A1.Feasibility / Route Development A2.Laboratory Process Development A3.Process Development / Scale-Up A4.GMP Clinical Development A5.Commercial GMP Supply
[1].Lin Q, Meloni D, Pan Y, Xia M, Rodgers J, Shepard S, et al. Enantioselective synthesis of Janus kinase inhibitor INCB018424 via an organocatalytic aza-Michael reaction. Org Lett. 2009;11(9):1999-2002. doi:10.1021/ol900350k.
[2].Crystalline forms of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile salts and preparation thereof. International patent WO2017125097A1. 2017.
[3].Novel polymorph of ruxolitinib hemifumarate and method of preparation. International patent WO2024172778A1. 2024.
[4].Quintás-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010;115(15):3109-17. doi:10.1182/blood-2009-04-214957.
关于仿制药原料药(generic APIs)的信息仅供一般参考和市场评估之用。监管状态、市场适用性、质量标准、专利及商业条款可能因国家/地区而异,并可能随时间变化。用户在作出任何监管、生产、投资或商业决策之前,应自行向相关监管机构及专业人士核实所有信息。 我们不向个人提供产品或服务。请严格遵守所有适用法律、法规,并仅按承诺用途使用相关产品或服务;严禁用于任何其他目的。
*本产品不用于诊断、治疗、治愈或预防任何疾病,仅供科研研究使用。